Sponsor: Bio-RadIn this Clinical OMICs webinar, sponsored by Bio-Rad, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for treatment of COVID-19.
Sponsor: ThermoFisher ScientificLarge cohort studies are essential to the discovery of protein biomarkers, and their validation is indispensable to clinical utility.
Sponsor: UltivueIn this exciting new webinar, sponsored by Ultivue, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.
Sponsor: QIAGENThis groundbreaking webinar will discuss how NGS technologies have aided clinicians in the diagnosis and treatment of hematologic cancer.
Sponsor: Bionano Genomics
Sponsor: Molecular MDCodevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.
Sponsor: Clinical OMICsExplore how liquid biopsies shape the diagnostic landscape and impact physician decision making and patient care.
Sponsor: IlluminaIn this Clinical OMICs webinar, sponsored by Illumina, we will discover how combining molecular and immune profiling's power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.
Sponsored content brought to you by What if every patient’s oncologist or lab testing personnel had access to an online digital encyclopedia of cancer mutations,...
Sponsor: ThermoFisher ScientificCoupling relatively routine datasets such as genomes and transcriptomes with newer types produces an “integrative Personal Omics Profile".